Biograil
Biograil is a Danish biotech company established in 2019, focused on developing innovative oral delivery technology for biologics and therapeutics that are traditionally administered via injections. The company leverages proprietary BIONDD® technology to transform injectable pharmaceuticals into convenient oral capsules, aiming to improve patient experience and expand treatment options. With a team of seasoned entrepreneurs and R&D experts, Biograil collaborates with major pharmaceutical companies and investors to advance its platform from pre-clinical stages to clinical trials and market readiness.
Industries
Nr. of Employees
small (1-50)
Biograil
Patents
Products
Ingestible capsule platform for gastric mucosal delivery of therapeutics
A platform device contained within a standard-size oral capsule that mechanically delivers active therapeutic macromolecules into the stomach mucosal wall to enable systemic absorption of biologics that typically require injection.
Ingestible capsule platform for gastric mucosal delivery of therapeutics
A platform device contained within a standard-size oral capsule that mechanically delivers active therapeutic macromolecules into the stomach mucosal wall to enable systemic absorption of biologics that typically require injection.
Services
Co-development, licensing and research collaborations with pharmaceutical companies to adapt injectable compounds for oral delivery using the capsule-based delivery platform; agreements can include research funding, milestones and licensing terms.
Co-development, licensing and research collaborations with pharmaceutical companies to adapt injectable compounds for oral delivery using the capsule-based delivery platform; agreements can include research funding, milestones and licensing terms.
Expertise Areas
- Oral biologics delivery
- Drug-device combination product development
- Preclinical development and bioavailability studies
- Injection-molded medical device manufacturing
Key Technologies
- Ingestible capsule-based delivery device
- Gastric mucosal (stomach wall) targeting
- Injection molding for polymer device manufacture
- Biodegradable polymer materials for devices
News & Updates
CTO Nikolaj Skak presented the BIONDD™ technology at the TIDES USA Conference in Boston on May 17, 2024, highlighting the platform for delivering biologics orally through a standard capsule.
Karsten Lindhardt, CEO and founder, presented the BIONDD™ technology at the CEO & Investor Conference in New York City on February 27, 2024.
Nikolaj Skak and Nina Mertz attended the APPSComms Pharmsci 360 conference in Orlando, FL, from October 22-25, 2023, discussing drug-delivery combination products and presenting a poster on BIONDD™ technology.
CEO Karsten Lindhardt presented the BIONDD™ technology at the TIDES conference in San Diego on April 8, 2025, focusing on oral delivery of biologics with bioavailability similar to subcutaneous administration.
Biograil signed a collaboration agreement with CSL Behring on July 17, 2024, to develop BIONDD™ technology for CSL proprietary compounds, aiming for effective oral drug delivery of injectable therapeutics.
On March 14, 2022, Biograil announced receiving a non-dilutive Innobooster grant of over 4 million DKK to support pre-clinical, manufacturing, and regulatory work for phase 1 trials.
CTO Nikolaj Skak presented the BIONDD™ technology at the TIDES USA Conference in Boston on May 17, 2024, highlighting the platform for delivering biologics orally through a standard capsule.
Karsten Lindhardt, CEO and founder, presented the BIONDD™ technology at the CEO & Investor Conference in New York City on February 27, 2024.
Nikolaj Skak and Nina Mertz attended the APPSComms Pharmsci 360 conference in Orlando, FL, from October 22-25, 2023, discussing drug-delivery combination products and presenting a poster on BIONDD™ technology.
CEO Karsten Lindhardt presented the BIONDD™ technology at the TIDES conference in San Diego on April 8, 2025, focusing on oral delivery of biologics with bioavailability similar to subcutaneous administration.
Biograil signed a collaboration agreement with CSL Behring on July 17, 2024, to develop BIONDD™ technology for CSL proprietary compounds, aiming for effective oral drug delivery of injectable therapeutics.
On March 14, 2022, Biograil announced receiving a non-dilutive Innobooster grant of over 4 million DKK to support pre-clinical, manufacturing, and regulatory work for phase 1 trials.